APA (7th ed.) Citation

Matsumoto, S., Kurihara, Y., Masuda, Y., Nara, K., Yuasa, M., Honda, A., . . . Kurokawa, M. (2026). Prognostic impact of procarbazine in R-MPV followed by reduced-dose whole-brain radiotherapy and cytarabine for primary central nervous system lymphoma. Leukemia & Lymphoma, 67(3), 638. https://doi.org/10.1080/10428194.2025.2604305

Chicago Style (17th ed.) Citation

Matsumoto, Shuhei, Yuya Kurihara, Yasutaka Masuda, Katsuhiko Nara, Mitsuhiro Yuasa, Akira Honda, Tappei Takada, and Mineo Kurokawa. "Prognostic Impact of Procarbazine in R-MPV Followed by Reduced-dose Whole-brain Radiotherapy and Cytarabine for Primary Central Nervous System Lymphoma." Leukemia & Lymphoma 67, no. 3 (2026): 638. https://doi.org/10.1080/10428194.2025.2604305.

MLA (9th ed.) Citation

Matsumoto, Shuhei, et al. "Prognostic Impact of Procarbazine in R-MPV Followed by Reduced-dose Whole-brain Radiotherapy and Cytarabine for Primary Central Nervous System Lymphoma." Leukemia & Lymphoma, vol. 67, no. 3, 2026, p. 638, https://doi.org/10.1080/10428194.2025.2604305.